EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss

Bilgeşah Kılıçtaş iD, Ahmet Ufuk Kılıçtaş iD, Rukiye Özçelik Erdem iD, Ahmet Oruç iD, Murat Araz iD, Melek Karakurt Eryılmaz iD, Mehmet Zahid Kocak iD, Hamdi Arbağ iD, Mehmet Artaç iD

Laryngoscope Investigative Otolaryngology · 2026-06 · 11 (3)

DOI: 10.1002/lio2.70484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 23.06.2026. Verfasst von Bilgeşah Kılıçtaş und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine Necmettin Erbakan University Konya Turkey. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Treatment adherence is a key determinant of outcomes in cancer patients and is influenced by multiple clinical and social factors. Hearing loss (HL) may contribute to communication barriers and treatment disruption. This study aimed to evaluate the relationship between HL and treatment adherence. Materials and Methods In this single‐center prospective observational study, 79 newly diagnosed cancer patients undergoing systemic therapy were evaluated with baseline pure‐tone audiometry. HL was categorized by severity. Treatment adherence was assessed based on missed cycles and treatment continuity. Clinical variables, including treatment‐related adverse events and caregiver presence, were analyzed using chi‐square tests and logistic regression analyses.

Results

HL was present in 67.1% of patients. Overall, 55.7% missed at least one treatment cycle. Missed cycles were more frequent in patients with HL ( p = 0.016), and higher HL severity was associated with increased treatment disruption ( p = 0.015). In univariate analysis, HL, older age, absence of a caregiver, and treatment‐related adverse events were associated with nonadherence. In multivariate analysis, only treatment‐related adverse events remained independently significant (OR = 93.2; p < 0.001).

Conclusion

Treatment adherence appears to be primarily driven by clinical factors, particularly treatment‐related toxicity. HL was associated with treatment disruption but was not an independent predictor and may act as a contributing factor. Level of Evidence 3.

Schlagwörter

Stichwörter der Autor:innen

cancerhearing disordershearing losspatient adherencequality of lifeside effect

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine Necmettin Erbakan University Konya Turkey.
  • Department of Otorhinolaryngology Konya City Hospital Konya Turkey.
  • Department of Otorhinolaryngology, Faculty of Medicine Necmettin Erbakan University Konya Turkey.

ORCID-Profile: Bilgeşah Kılıçtaş, Ahmet Ufuk Kılıçtaş, Rukiye Özçelik Erdem, Ahmet Oruç, Murat Araz, Melek Karakurt Eryılmaz, Mehmet Zahid Kocak, Hamdi Arbağ, Mehmet Artaç

Zitieren

APA

Kılıçtaş, B., Kılıçtaş, A. U., Erdem, R. Ö., Oruç, A., Araz, M., Eryılmaz, M. K., Kocak, M. Z., Arbağ, H., & Artaç, M. (2026). Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss. Laryngoscope Investigative Otolaryngology, 11(3). https://doi.org/10.1002/lio2.70484

Vancouver

Kılıçtaş B, Kılıçtaş AU, Erdem RÖ, Oruç A, Araz M, Eryılmaz MK, et al. Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss. Laryngoscope Investigative Otolaryngology. 2026;11(3). doi:10.1002/lio2.70484

BibTeX
@article{Klta2026,
  author = {Kılıçtaş, Bilgeşah and Kılıçtaş, Ahmet Ufuk and Erdem, Rukiye Özçelik and Oruç, Ahmet and Araz, Murat and Eryılmaz, Melek Karakurt and Kocak, Mehmet Zahid and Arbağ, Hamdi and Artaç, Mehmet},
  title = {Clinical and Social Determinants of Treatment Adherence in Cancer Patients: The Contributory Role of Hearing Loss},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2026},
  volume = {11},
  number = {3},
  doi = {10.1002/lio2.70484}
}
Kostenlos starten →